Renaissance of psychedelic therapy and its significance for Ukraine
Abstract
Over the past decades, psychopharmacology has not been able to introduce new revolutionary drugs for psychiatry, while the classic antidepressants currently present on the market are of little efficacy. A new solution to these problems in medicine promises to be the second “psychedelic revolution”, which has been actively developing since the beginning of this century. A number of psychedelic substances, in particular MDMA, psilocybin, DMT, LSD and ketamine, are seen as the most promising treatment agents. Psychedelics have the extraordinary ability to produce rapid and lasting changes in the structure and function of neurons and to improve the mental state of patients even after a single dose. Evidence from well-designed and well-controlled studies suggests that these compounds are effective in depression, anxiety, PTSD and addiction, do not cause physical dependence or withdrawal, and have very low or no incidence of serious adverse reactions such as psychotic episodes. There is an urgent need to legalize psychedelic therapy in Ukraine.
Downloads
References
Albaugh B., Anderson P. (1974) Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry 131:4. https://doi.org/10.1176/ajp.131.11.1247
Andersen K. A, Carhart-Harris R, Nutt D. J, Erritzoe D. (2021) Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand. 143:101–18. https://doi.org/10.1111/acps.13249
Bache C. M. (1991). Mysticism and psychedelics: the case of the dark night. J. Relig. Health 30, 215–236. https://doi.org/10.1007/BF00986399
Baggott M. J. (2015). Psychedelics and creativity: a review of the quantitative literature. PeerJ PrePrints 3:e1202ve1201. https://doi.org/10.7287/peerj.preprints.1202v1
Ballard E. D., Zarate C. A. (2020). The role of dissociation in ketamine’s antidepressant effects. Nat. Commun. 11:6431. https://doi.org/10.1038/s41467-020-20190-4
Bandeira I. D., Lins-Silva D. H., Cavenagh, V. B., et al. (2022). Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review of Psychiatry, 30(2), 135-145 https://doi.org/10.1097/hrp.0000000000000330
Barker S. A, McIlhenny E. H, Strassman R. (2012) A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Testing and Analysis 4(7–8): 617–635. https://doi.org/10.1002/dta.422
Barker S. A. (2018). N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. Frontiers in neuroscience, 12, 536. https://doi.org/10.3389/fnins.2018.00536
Barnes D. T. (1970) The uses and abuses of L.S.D. and other hallucinogenic drugs. Aust N Z J Psychiatry 4:170–3. https://doi.org/10.3109/00048677009159331
Barrett F. S., Doss M. K., Sepeda N. D., et al. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci. Rep. 10, 1–14. https://doi.org/10.1038/s41598-020-59282-y
Barrett F. S., Johnson M. W., Griffiths R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. 29, 1182–1190. https://doi.org/10.1177/0269881115609019
Beliveau V., Ganz M., Feng L., et al. (2017) A high-resolution in vivo atlas of the human brain’s serotonin system. J. Neurosci. 37(1), 120-128. https://doi.org/10.1523/JNEUROSCI.2830-16.2016
Bennett R. (2019). Paradigms of Ketamine Treatment. MAPS. https://maps.org/news/bulletin/articles/436-maps-bulletin-spring-2019-vol-29-no-1/7718-paradigms-of-ketamine-treatment-spring-2019
Berman R. M., Cappiello A., Anand A., et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351–354. https://doi.org/10.1016/s0006-3223(99)00230-9
Bogenschutz M. P, Forcehimes A. A, Pommy J. A, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29:289–9. https://doi.org/10.1177/0269881114565144
Bogenschutz M. P, Forcehimes A. A. (2017) Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J Hum Psychol. 57:389–414. https://doi.org/10.1177/0022167816673493
Bogenschutz M. P, Johnson M. W. (2016) Classic hallucinogens in the treatment of addictions. Progress Neuro-Psychopharmacol Biol Psychiatry. 64:250–8. https://doi.org/10.1016/j.pnpbp.2015.03.002
Bonnet U. (2015). Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction. Journal of Psychoactive Drugs, 47(4), 276-285. https://doi.org/10.1080/02791072.2015.1072653
Bouso J. C., Gonzбlez D., Fondevila S., et al. (2012). Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. Plos One, e42421. https://doi.org/10.1371/journal.pone.0042421
Brouwer A, Carhart-Harris R. L. (2020) Pivotal mental states. J Psychopharmacol. 35:319–52. https://doi.org/10.1177/0269881120959637
Busch A. K, Johnson W. C. (1950) L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst 11:241–3. https://doi.org/10.1177/204512531664044
Carbonaro T. M, Bradstreet M. P, Barrett F. S, et al. (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology. 30(12):1268-1278. https://doi.org/10.1177/0269881116662634
Carhart-Harris R. L, Nutt D. J. (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 31:1091–120. https://doi.org/10.1177/0269881117725915
Carhart-Harris R., Bolstridge M., Rucker J., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619-627. https://doi.org/10.1016/S2215-0366(16)30065-7
Carstairs S. D, Cantrell F. L. (2010) Peyote and mescaline exposures: A 12-year review of a statewide poison center database. Clin Toxicol 48: 350–353. https://doi.org/10.3109/15563650903586745
Cipriani A., Williams T., Nikolakopoulou A., et al. (2018) Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med 48:1975–84. https://doi.org/10.1017/S003329171700349X
Coventry P. A., Hudson J. L., Kontopantelis E., et al. (2014). Characteristics of effective collaborative care for treatment of depression: a systematic review and meta-regression of 74 randomised controlled trials. PloS one, 9(9), e108114. https://doi.org/10.1371/journal.pone.0108114nk
Dalgarno P., Shewan D. (2005). Reducing the risks of drug use: the case for set and setting. Addict. Res. Theory 13, 259–265. https://doi.org/10.1080/16066350500053562
Dames S., Kryskow P., Watler C. (2022). A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression. Front. Psychiatry 12:803279. https://doi.org/10.3389/fpsyt.2021.803279
Das S., Barnwal P., Ramasamy A., et al. (2016) Lysergic acid diethylamide: a drug of ‘use'? Ther Adv Psychopharmacol 6:214–8. https://doi.org/10.1177/2045125316640440
Davis A. K, So S., Lancelotta R., et al. (2019) 5-methoxy-N, N-dimethyltryptamine (used in a naturalistic group setting is associated with unintended improvements in depression and anxiety). The American Journal of Drug and Alcohol Abuse 45(2): 161–169. https://doi.org/10.1080/00952990.2018.1545024
Davis A. K., Barrett F. S., Griffiths R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of contextual behavioral science, 15, 39-45. https://doi.org/10.1016/j.jcbs.2019.11.004
Davis A. K., Barsuglia J. P., Lancelott, R., et al. (2018). The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology, 32(7), 779-792. https://doi.org/10.1177/02698811187690
Davis, A. K., Barrett, F. S., May, D. G., et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
de Veen B., Schellekens A., Verheij M., Homberg J. R. (2017) Psilocybin for treating substance use disorders? Expert Rev Neurother 17(2):203–12. https://doi.org/10.1080/14737175.2016.1220834
Dinis-Oliveira R. J., Pereira C. L., da Silv, D. D. (2019). Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Current molecular pharmacology, 12(3), 184. https://doi.org/10.2174%2F1874467211666181010154139
Doblin R. (2002) A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoact Drugs 34:185–194. https://doi.org/10.1080/02791072.2002.10399952
Dore J., Turnipseed B., Dwyer S., et al. (2019). Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J. Psychoactive Drugs 51, 189–198. https://doi.org/10.1080/02791072.2019.1587556
dos Santos R. (2013). Safety and side effects of ayahuasca in humans—an overview focusing on developmental toxicology. Journal of psychoactive drugs, 45(1), 68-78. https://doi.org/10.1080/02791072.2013.763564
Du R., Han R., Niu K., et al. (2022). The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis. Frontiers in psychiatry, 13, 813103. https://doi.org/10.3389/fpsyt.2022.813103
Duncan Jr W. C., Sarasso S., Ferrarelli F., et al. (2013). Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. International Journal of Neuropsychopharmacology, 16(2), 301-311. https://doi.org/10.1017/s1461145712000545
El-Seedi H. R., De Smet P. A, Beck O., et al. (2005) Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol 101:238–42. https://doi.org/10.1016/j.jep.2005.04.022
Ermakova A. O., Dunbar F., Rucker J., Johnson, M. (2022). A narrative synthesis of research with 5-MeO-DMT. Journal of psychopharmacology (Oxford, England), 36(3), 273–294. https://doi.org/10.1177/02698811211050543
Fantegrossi W. E, Murnane K. S, Reissig C. J. (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17–3. https://doi.org/10.1016/j.bcp.2007.07.018
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. FDA NEWS RELEASE, March 05, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
Feduccia A. A., Mithoefer M. C. (2018). MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog. Neuropsychopharmacol. Biol. Psychiatry 84, 221–228. https://doi.org/10.1016/j.pnpbp.2018.03.003
Fischman L. G. (2019). Seeing without self: discovering new meaning with psychedelic-assisted psychotherapy. Neuropsychoanalysis 21, 53–78. https://doi.org/10.1080/15294145.2019.1689528
Forstmann M., Yudkin D. A., Prosser A. M., et al. (2020). Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc. Natl. Acad. Sci. U.S.A. 117, 2338–2346. https://doi.org/10.1073/pnas.1918477117
Fournier J. C, DeRubeis R. J, Hollon SD, et al. (2010) Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis. JAMA. 303(1):47–53. https://doi.org/10.1001/jama.2009.1943
Frederking W. (1955). Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J. Nerv. Mental Dis. 121, 262–266. https://doi.org/10.1097/00005053-195503000-00010
Friedman M. J, Marmar C. R, Baker D. G., et al. (2007) Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 68(5):711–20. https://doi.org/10.4088/jcp.v68n0508
Fuentes J. J., Fonseca F., Elices M., et al. (2020). Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Frontiers in psychiatry, 943. https://doi.org/10.3389/fpsyt.2019.00943
Gabermann V. (1978) Estimation of mescaline and pellotine in Lophophora coulter plants (Cactaceae) by means of the oscillographic polarography. Biokhimiia 43: 246–51
Gable R. S. (1993) Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse 19:263–1. https://doi.org/10.3109/00952999309001618
Garcia-Romeu A., Griffiths R., Johnson M., (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr. Drug Abuse Rev. 7, 157–164. https://doi.org/10.2174/1874473708666150107121331
Garrity J. F. (2000) Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing. Med Anthropol Q;14:521–42. https://doi.org/10.1525/maq.2000.14.4.521
Gillin J. C, Tinklenberg J., Stoff D. M., et al. (1976) 5-Methoxy-N,N-dimethyltryptamine: Behavioral and toxicological effects in animals. Biological Psychiatry 11(3): 355–358.
Gonzбlez D., Cantillo J., Pйrez I., et al. (2020). Therapeutic potential of ayahuasca in grief: a prospective, observational study. Psychopharmacology 237, 1171–1182. https://doi.org/10.1007/s00213-019-05446-2
Grabski M., Borissova A., Marsh B., et al. (2020). Ketamine as a mental health treatment: are acute psychoactive effects associated with outcomes? A systematic review. Behav. Brain Res. 392:112629. https://doi.org/10.1016/j.bbr.2020.112629
Graeff F. G, Guimaraes F. S, De Andrade T. G, Deakin J. F. (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 54:129–41. https://doi.org/10.1016/0091-3057(95)02135-3
Griffiths R. R, Johnson M. W, Richards W. A, et al. (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 31(1):49–69. https://doi.org/10.1177/0269881117731279
Griffiths R. R., Johnson M. W., Carducci M. A., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181–1197. https://doi.org/10.1177/0269881116675513
Griffiths R., Richards W., Johnson M., et al. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 22, 621–632. https://doi.org/10.1177/0269881108094300
Grinspoon L., Balakar J. B. (1997). Psychedelic drugs reconsidered. New York, NY: The Lindesmith Center.
Grob C. S, Danforth A. L, Chopra G. S, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71. https://doi.org/10.1001/archgenpsychiatry.2010.116
Grof S. (2008). LSD Psychotherapy: The Healing Potential of Psychedelic Medicine. Ben Lomond, CA: MAPS.
Grof S., Halifax J., Kьbler-Ross E. (1978) The Human Encounter With Death. EP Dutton: New York, NY.
Halpern J. H, Pope H. G. (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend. 53:247–56. https://doi.org/10.1016/S0376-8716(98)00129-X
Halpern J. H, Pope H. G. (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend. 53:247–56. https://doi.org/10.1016/S0376-8716(98)00129-X
Halpern J. H., Sherwood A. R., Hudson J. I., et al. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58: 624–631. https://doi.org/10.1016/j.biopsych.2005.06.038
Hartogsohn I. (2018). The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Front. Neurosci. 12:129. https://doi.org/10.3389/fnins.2018.00129
Hawkswell S. (2021) TheraPsil: Open Letter to Heatlh Canada. TheraPsil.
Hearn B. (2021). Psychedelics, mystical experiences, and meaning making: a renegotiation process with the challenges of existence. J. Humanist. Couns. 60, 180–196. https://doi.org/10.1002/johc.12164
Heffter A. (1898). Ueber Pellote: Beitrдge zur chemischen und pharmakologischen Kenntniss der Cacteen Zweite Mittheilung [Concerning Peyote: Contributions to the chemical and pharmacological understanding of Cacti, second communication]. Naunyn-Schmiedeberg’s Archives of Pharmacology, 40, 385-429.
Hendricks P. S., Thorne C. B., Clark,C. B., et al. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 29, 280–288. https://doi.org/10.1177/0269881114565653
Hoffer A. (1967). A program for treatment of alcoholism: LSD, malvaria, and nicotinic acid. In Abramson H. A. (Ed.), The use of LSD in psychotherapy and alcoholism (pp. 343-406). Indianapolis, IN: Bobbs-Merrill.
Hofmann A. (1979). How LSD originated. Journal of Psychedelic Drugs, 11, 53-60. https://doi.org/10.1080/02791072.1979.10472092
Holze F., Vizeli P., Mьller F., et al. (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 45:462–71. https://doi.org/10.1038/s41386-019-0569-3
Hoskins M., Pearce J., Bethell A., et al. (2018). Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. The British Journal of Psychiatry, 206(2), 93-100. https://doi.org/10.1192/bjp.bp.114.148551
Howes O. D., Thase M. E., Pillinge, T. (2021). Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry, 1-15. https://doi.org/10.1038/s41380-021-01200-3
Johansen P.-Ш., Krebs T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: a population study. J. Psychopharmacol. 29, 270–279. https://doi.org/10.1177/0269881114568039
Johnson M. W, Garcia-Romeu A, Cosimano M. P, Griffiths R. R. (2014) Pilot study of the 5-HT2A R agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28:983–2. https://doi.org/10.1177/0269881114548296
Johnson M. W., Garcia-Romeu A., Griffiths R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug Alcohol Abuse 43, 55–60. https://doi.org/10.3109/00952990.2016.1170135
Johnson M., Richards W., Griffiths R. (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–20. https://doi.org/10.1177/0269881108093587
Kamboj S. K., Kilford E. J., Minchin S., et al. (2015). Recreational 3, 4-methylenedioxy-N-methylamphetamine (MDMA) or ‘ecstasy’and self-focused compassion: preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices. J. Psychopharmacol. 29, 961–970. https://doi.org/10.1177/0269881115587143
Kapadia G. J, Fayez M. (1970) Peyote constituents: Chemistry, biogenesis, and biological effects. J Pharm Sci 59: 1699–1727. https://doi.org/10.1002/jps.2600591202
Kirsch I. (2014) Antidepressants and the placebo effect. Z Psychol. 222:128–34. https://doi.org/10.1027/2151-2604/a000176
Koelle G. B. (1958) The pharmacology of mescaline and D-lysergic acid diethylamide (LSD). N Engl J Med 258: 25–32. https://doi.org/10.1056/NEJM195801022580106
Kolp E., Friedman H., Krupitsky E., et al. (2014). Ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications. Int. J. Transpers. Stud. 33, 84–140. https://doi.org/10.24972/ijts.2014.33.2.84
Krystal J. H., Abdallah C. G., Averill L. A., et al. (2017) Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep 19:74. https://doi.org/10.1007/s11920-017-0829-z
Lafrance A, Robison R. Psychedelics and Eating Disorders. (2021). https://www.edcatalogue.com/psychedelics-eating-disorders/
Lara D. R, Bisol L. W, Munari L. R. (2013) Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. Oct;16:2111–17. https://doi.org/10.1017/S1461145713000485
Letcher A. (2008). Shroom. New York, NY: Harper Collins
Leuner H. (1967). Present state of psycholytic therapy and its possibilities. In Abramson H. A. (Ed.), The use of LSD in psychotherapy and alcoholism (pp. 101-116). Indianapolis, IN: Bobbs-Merrill.
Luoma J. B, Sabucedo P, Eriksson J, et al. (2019) Toward a contextual psychedelic-assisted therapy: perspectives from acceptance and commitment therapy and contextual behavioral science. J Context Behav Sci. 14:136–45. https://doi.org/10.1016/j.jcbs.2019.10.003
MacLean K. A, Johnson M. W, Griffiths R. R. (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25(11):1453–61. https://doi.org/10.1177/0269881111420188
MacLean K. A., Leoutsakos J. M., Johnson M. W., Griffiths R. R. (2012). Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J. Sci. Study Relig. 51, 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685
MAPS (2020) Israel Embraces Research on MDMA-Assisted Therapy for PTSD. MAPS Press Release. https://maps.org/news/media/press-release-israel-embraces-research-on-mdma-assisted-psychotherapy-for-ptsd/
Martinotti G., Chiappini S., Pettorrus, M., et al. (2021). Therapeutic potentials of ketamine and esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (sud) and Eating Disorders (ed): a review of the current literature. Brain Sciences, 11(7), 856. https://doi.org/10.3390/brainsci11070856
Masters R., Houston J. (2000). The varieties of psychedelic experience: The classic guide to the effects of LSD on the human psyche. Rochester, VT: Park Street Press.
McKenna D. J, Towers G. H, Abbott F. (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J Ethnopharmacol. 10:195-223 https://doi.org/10.1016/0378-8741(84)90003-5
Metzner R., Adamson S. (2001) Using MDMA in healing, psychotherapy and spiritual practice. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester, USA
Miller G. (2010). Is pharma running out of brainy ideas? Science. 329, 502–504. https://doi.org/10.1126/science.329.5991.502
Mitchell J. M., Bogenschutz M., Lilienstein A., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033. https://doi.org/10.1038/s41591-021-01336-3
Moreno F. A, Wiegand C. B, Taitano E. K, Delgado P. L. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735–0. https://doi.org/10.4088/jcp.v67n1110
Mуrу L., Simon K., Bбrd I., Rбcz J. (2011). Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users. J. Psychoactive Drugs 43, 188–198. https://doi.org/10.1080/02791072.2011.605661
Murrough J. W, Perez A. M, Pillemer S., et al. (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250–56. https://doi.org/10.1016/j.biopsych.2012.06.022
Nichols D. (1986). Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens. Journal of Psychoactive Drugs. 18 (4): 305–13. https://doi.org/10.1080/02791072.1986.10472362
Nichols D. E. (2016) Psychedelics. Pharmacol Rev 68:264–355. https://doi.org/10.1124/pr.115.011478
Nutt D. J, King L. A, Phillips L. D. (2010) Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 376:1558–5. https://doi.org/10.1016/S0140-6736(10)61462-6
Olson D. E. (2018) Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 12:1179069518800508. https://doi.org/10.1177/1179069518800508
Oram M. (2018). The trials of psychedelic therapy: LSD psychotherapy in America. JHU Press.
Osmond H., Smythies J. (1952) Schizophrenia: A new approach. J Ment Sci 98: 309–315. https://doi.org/10.1192/bjp.98.411.309
Pahnke W. (1963) Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Ph.D. dissertation. Harvard University.
Pahnke W. (1969). Psychedelic drugs and mystical experience. Int. Psychiatry Clin. 5:149.
Pahnke W. N., Kurland A. A., Unger S., et al. (1970). The experimental use of psychedelic (LSD) psychotherapy. JAMA 212, 1856–1863. https://doi.org/10.1001/jama.1970.03170240060010
Palhano-Fontes F., Barreto D., Onias H., et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol. Med. 49, 655–663. https://doi.org/10.1017/S0033291718001356
Passie T, Seifert J, Schneider U, Emrich H. M. (2002) The pharmacology of psilocybin. Addict Biol 7:357–64. https://doi.org/10.1080/1355621021000005937
Passie T., Halpern J. H., Stichtenoth D. O., et al. (2008). The Pharmacology of Lysergic Acid Diethylamide: A Review. CNS Neuroscience & Therapeutics, 14: 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x
Peroutka S. J, Newman H., Harris H. (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1:273–7.
Petranker R., Anderson T., Farb N. (2020) Psychedelic research and the need for transparency: Polishing Alice's Looking Glass. Front Psychol. 11:1681. https://doi.org/10.3389/fpsyg.2020.01681
Pochettino M. L, Cortella A. R, Ruiz M. (1999) Hallucinogenic snuff from Northwestern Argentina: Microscopical identification of Anadenanthera colubrina var. cebil (fabaceae) in powdered archaeological material. Economic Botany 53(2): 127–132. https://doi.org/10.1007/BF02866491
Pollan M. (2018). How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. Penguin.
Popova V., Daly E. J., Trivedi M., et al. (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176: 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
Pribish A., Wood N., Kalava, A. (2020). A review of nonanesthetic uses of ketamine. Anesthesiology research and practice, 2020:5798285. https://doi.org/10.1155/2020/5798285
Reiff C. M, Richman E. E, Nemeroff C. B, Carpenter L.L, et al. (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 177:391–410. https://doi.org/10.1176/appi.ajp.2019.19010035
Riba J., Rodriguez-Fornells A., Urbano G., et al. (2001). Subjective effects and tolerability of the south American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology 154, 85–95. https://doi.org/10.1007/s002130000606
Roseman L., Nutt D. J., Carhart-Harris R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 8:974. https://doi.org/10.3389/fphar.2017.00974
Sarris J., Perkins D., Cribb L., et al. (2021). Ayahuasca use and reported effects on depression and anxiety symptoms: an international cross-sectional study of 11,912 consumers. Journal of Affective Disorders Reports, 4, 100098. https://doi.org/10.1016/j.jadr.2021.100098
Schmid Y, Gasser P, Oehen P, Liechti M. E. (2021) Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol. 35:362–74. https://doi.org/10.1177/0269881120959604
Schultes R. E., Hoffman, A., Rдtsch C. (2001). Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Revised Edition. Rochester, VT: Healing Arts Press.
Sessa B. (2016) MDMA and PTSD treatment: PTSD: from novel pathophysiology to innovative therapeutics. Neurosci Lett. 2016:S0304-3940(16)30490-6.). https://doi.org/10.1016/j.neulet.2016.07.004
Sherwood J. N., Stolaroff M. J., Harman W. W. (1962). The psychedelic experience: A new concept in psychotherapy. Journal of Neuropsychiatry, 4, 69-80. https://doi.org/10.1080/02791072.1968.10524522
Sills M. A, Lucki I., Frazer A. (1985) Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. Life Sciences 36(26): 2463–2469. https://doi.org/10.1016/0024-3205(85)90142-0
Sinyor M., Schaffer, A., Levitt A. (2010) The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review. Can. J. Psychiatry. 55, 126–135, https://doi.org/10.1177/070674371005500303
Sloshower J., Guss J., Krause R., et al. (2020). Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. J. Contextual Behav. Sci. 15, 12–19. https://doi.org/10.1016/j.jcbs.2019.11.002
Snyder W. U. (1945). An investigation of the nature of non-directive psychotherapy. J. Gen. Psychol. 33, 193–223. https://doi.org/10.1080/00221309.1945.10544506
Stefulj J, Jernej B, Cicin-Sain L, et al. (2000) mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun 14(3):219–24. https://doi.org/10.1006/brbi.1999.
Stein M. B, Kline N. A, Matloff J. L. (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry 159:1777–1779. https://doi.org/10.1176/appi.ajp.159.10.1777
Strassman R. J. (1984) Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172:577–5. https://doi.org/10.1097/00005053-198410000-00001
Studerus E., Kometer M., Hasler F., Vollenweider F. X. (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 25:1434–52. https://doi.org/10.1177/0269881110382466
Sumner R. L., Chacko E., McMillan R., et al. (2021). A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties. J. Psychopharmacol. 35, 946–961. https://doi.org/10.1177/0269881121998321
The Lancet Global H. (2020) Mental health matters. Lancet Glob Health. 8:e1352. https://doi.org/10.1016/S2214-109X(20)30432-0
Thomas G., Lucas P., Capler N. R., et al. (2013). Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr. Drug Abuse Rev. 6, 30–42. https://doi.org/10.2174/15733998113099990003
Trout K. (2007) Trout’s Notes on Some Simple Tryptamines: A Brief Overview & Resource Compendium. Mydriatic Productions.
Uthaug M. V, Davis A. K, Haas T. F, et al. (2022) The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology 36(3):309-320. https://doi.org/10.1177/02698811211013583
Uthaug M. V., Lancelotta R., Szabo A., et al. (2020) Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: Effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology 237(3): 773–785. https://doi.org/10.1007/s00213-019-05414-w
van Amsterdam J., Nutt D., Phillips L., van den Brink W. (2015) European rating of drug harms. J Psychopharmacol 29:655–0. https://doi.org/10.1177/0269881115581980
Wallace A. F. (1959) Cultural determinants of response to hallucinatory experience. AMA Arch Gen Psychiatry 1: 58–69. https://doi.org/10.1001/archpsyc.1959.03590010074009
Warden D., Rush A. J., Trivedi M. H., et al. (2007) The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9, 449– 459, https://doi.org/10.1007/s11920-007-0061-3
Watts R., Day C., Krzanowski J., et al. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J. Hum. Psychol. 57, 520–564. https://doi.org/10.1177/0022167817709585
Weil A. T, Davis W (1994) Bufo alvarius: A potent hallucinogen of animal origin. Journal of Ethnopharmacology 41(1–2): 1–8. https://doi.org/10.1016/0378-8741(94)90051-5
Welwood J. (1982). Principles of inner work: psychological and spiritual. J. Transpers. Psychol. 16:1984.
Wheeler S.W, Dyer N. L. (2020) A systematic review of psychedelic-assisted psychotherapy for mental health: an evaluation of the current wave of research and suggestions for the future. Psychol Conscious Theor Res Pract. 7:279. https://doi.org/10.1037/cns0000237
White P. F, Way W., Trevor A. J. (1982) Ketamine—its pharmacology and therapeutic uses. Anesthesiology 56(2):119–136. https://doi.org/10.1097/00000542-198202000-00007
Whittaker E., Dadabayev A. R., Joshi S. A., Glue,P. (2021). Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology, 11, 20451253211056743. https://doi.org/10.1177/20451253211056743
Wilkinson S. T., Holtzheimer P. E., Gao S., et al. (2019). Leveraging neuroplasticity to enhance adaptive learning: The potential for synergistic somatic-behavioral treatment combinations to improve clinical outcomes in depression. Biol. Psychiatry 85, 454–465. https://doi.org/10.1016/j.biopsych.2018.09.004
Winkelman M. (2014). Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Current drug abuse reviews, 7(2), 101-116. https://doi.org/10.2174/1874473708666150107120011
Wolff M, Evens R, Mertens L. J, et al. (2020) Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry. 11:5. https://doi.org/10.3389/fpsyt.2020.00005
Zarate C. A Jr, Brutsche N. E, Ibrahim L., et al. (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. Jun 1;71:939–46. https://doi.org/10.1016/j.biopsych.2011.12.010
Zimmerman J. M, Maren S. (2010) NMDA receptor antagonism in the basolateral but not central amygdala blocks the extinction of Pavlovian fear conditioning in rats. Eur J Neursci 31:1664–1670. https://doi.org/10.1111/j.1460-9568.2010.07223.x
Abstract views: 98 PDF Downloads: 315
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
